Alfuzest-D Tablet
Alfuzosin 10 mg Extended Release + Dutasteride 0.5 mg Tablets — Dual BPH Therapy
| Composition | Alfuzosin 10 mg Extended Release + Dutasteride 0.5 mg |
|---|---|
| Dosage Form | Bilayered Extended Release Tablet |
| Pack Type | Alu-Alu Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 1650 |
| Therapy | G.P. + Urology — Alpha-1 Blocker + 5-Alpha-Reductase Inhibitor |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Alfuzest-D Tablet
Alfuzest-D Tablet combines Alfuzosin 10 mg Extended Release with Dutasteride 0.5 mg — a clinically validated dual-mechanism therapy for moderate-to-severe benign prostatic hyperplasia (BPH). The two drugs address BPH through complementary pathways: Alfuzosin provides rapid symptomatic relief by relaxing prostatic smooth muscle, while Dutasteride shrinks prostate size over months by inhibiting androgen-driven tissue growth.
Alfuzosin acts on alpha-1A/1D adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle and improving urine flow within days. Dutasteride is a dual 5-alpha-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT) — the androgen responsible for prostatic enlargement — reducing prostate volume by 20–25% over 6–12 months and lowering the long-term risk of acute urinary retention and BPH-related surgery.
Alfuzest-D is manufactured by Trumac Healthcare under WHO-GMP conditions and is available for monopoly-based PCD pharma franchise and third-party manufacturing — a high-value urology SKU with strong prescription stickiness.
Indications
- Moderate-to-severe lower urinary tract symptoms (LUTS) of BPH with enlarged prostate
- BPH where alpha-blocker monotherapy is inadequate
- Long-term reduction of prostate volume and acute urinary retention risk
- Prevention of BPH progression
Mechanism of Action
Alfuzosin selectively blocks alpha-1A/1D adrenergic receptors in the prostate, bladder neck and urethra, relaxing smooth muscle tone for immediate symptom relief. Dutasteride inhibits both type 1 and type 2 isoforms of 5-alpha-reductase, dramatically reducing serum and intra-prostatic DHT levels, which over months produces apoptosis of androgen-dependent prostatic tissue and a 20–25% reduction in prostate volume.
Dosage & Administration
Adults: one tablet once daily, taken at the same time each day with or without food. Swallow whole. Long-term therapy required for full Dutasteride benefit (6–12 months for prostate-volume reduction).
Side Effects
Alfuzosin: dizziness, postural hypotension, headache, fatigue. Dutasteride: decreased libido, erectile dysfunction, ejaculation disorders, gynaecomastia, breast tenderness. Combined regimen may increase ejaculatory dysfunction frequency.
Contraindications & Precautions
Hypersensitivity to either component or other 5-alpha-reductase inhibitors (finasteride). Women — particularly pregnant or potentially pregnant women — must not handle leaking capsules (teratogenicity risk). Severe hepatic impairment. Concomitant potent CYP3A4 inhibitors. Not for use in children. Inform ophthalmologist before cataract surgery (IFIS risk).
Storage
Store below 30 °C in a dry place, protected from light and moisture.
Alfuzest-D Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Alfuzest-D Tablet used for?
Alfuzest-D Tablet is a fixed-dose combination of Alfuzosin 10 mg ER and Dutasteride 0.5 mg, used for moderate-to-severe benign prostatic hyperplasia (BPH) with enlarged prostate — providing both immediate symptom relief and long-term prostate-volume reduction.
How long until I see results from Alfuzest-D?
Alfuzosin produces symptom relief within days to weeks. Dutasteride's prostate-shrinking effect develops over 6–12 months of continuous therapy; full benefit on retention risk reduction is seen with long-term use.
Is Alfuzest-D available for PCD pharma franchise?
Yes, Trumac Healthcare offers Alfuzest-D Tablet on monopoly-based PCD pharma franchise across India, and for third-party manufacturing.
Can women take Alfuzest-D?
No. Alfuzest-D is indicated only for adult men with BPH. Pregnant women must not even handle the medication due to the teratogenic potential of Dutasteride.
Is Alfuzest-D WHO-GMP certified?
Yes, Alfuzest-D Tablet is manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Alfuzest-10 PR Tablet — Alfuzosin 10 mg (Prolonged Release)
- Alkite-B6 Syrup — Potassium Citrate 1100 mg + Magnesium Citrate 375 mg + Vitamin B6 20 mg / 5 ml
- Alkite-B6 Tablet — Potassium Magnesium Citrate 978 mg + Magnesium Citrate 263.10 mg + Vitamin B6 15 mg